AzTrials
AzTrials

HypothermiaNCT03697122

Heated Humidified Breathing Circuit Rewarming in Hypothermic Post Cardiopulmonary Bypass Patients.

A study testing Heated Humidified Breathing Circuit and Forced Air Blanket in people with Hypothermia and Rewarming, run by Duke University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Hypothermia on admission to the intensive care unit (ICU) following cardiopulmonary bypass (CPB) is common. The investigators propose that rewarming hypothermic (≤ 35 C) patients admitted to the intensive care unit following procedures using CPB with heated humidified breathing circuits (HHBC) in addition to… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hypothermia, Rewarming
What is being tested?
Heated Humidified Breathing Circuit and Forced Air Blanket
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
14 participants
Where
1 siteUnited States
Study dates
1 Apr 2019to 15 Jun 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Admission to intensive care unit following surgical procedure involving cardiopulmonary bypass.
  • Admission temperature ≤ 35.0 C.

Who cannot join

  • Patients placed on extracorporeal membrane oxygenation intra-operatively, or during first 24 hours after ICU admission.
  • Any additional surgical procedures in the first 24 hours days after initial surgery e.g. Chest exploration for bleeding, Open Chest, Non-cardiac surgery such as colectomy for ischemic gut, etc.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Duke University Hospital

    Durham, North Carolina, 27710

Other trials in United States

About this study

Hypothermia on admission to the intensive care unit (ICU) following cardiopulmonary bypass (CPB) is common. The investigators propose that rewarming hypothermic (≤ 35 C) patients admitted to the intensive care unit following procedures using CPB with heated humidified breathing circuits (HHBC) in addition to conventional forced air warming blankets will shorten time to normothermia. Secondarily it may shorten time to extubation, improve coagulopathy, and metabolic derangements seen with hypothermia.

Read the detailed description

Hypothermia on admission to the intensive care unit (ICU) following cardiopulmonary bypass (CPB) is common. Cooling and rewarming during CPB and deep hypothermic circulatory arrest (DHCA) takes considerable time and contributes to the post-procedural coagulopathy and physiologic perturbations. Core body parts (trunk and head) rewarm more quickly than peripheral parts (extremities). After disconnecting from CPB the body is allowed to self equilibrate. The normal vasoconstriction response is impaired by the administered anaesthesia. Hence, heat distribution takes place from the warm core to the colder periphery. This causes an afterdrop: a decrease in the temperature of the core organs. After-drop may contribute to post-operative complications such as shivering, coagulopathy, increased myocardial stress, increased wound infections, metabolic acidosis, delayed extubation and prolonged ICU length of stay (LOS).

The use of the active warming via traditional methods (ie forced air warming blankets) and Heated Humidified breathing circuits (HHBC) via ANAPOD Heated Humidification System® (ANAPOD) may shorten time to normothermia. Secondarily it may shorten time to extubation, improve coagulopathy, and metabolic derangements seen with hypothermia.

Sample and Study Design- The investigators will prospectively collect data for 14 enrolled non-patients who will receive active warming via both forced air warming blankets and Heated Humidified breathing circuits (HHBC). Retrospective data will be obtained retrospectively for 28 matched patients from two years prior to initiation of the trial, who received warming only via forced air warming blankets.

Data Collection Plan- Data will be extracted and collected by the Duke Department of Anesthesiology IT analyst, who will review and extract information from the patient's chart via Epic/ Maestro Care, or manually if necessary.

Data Evaluation- Descriptive statistics will be used to evaluate patient demographics and clinical characteristics. Descriptive statistics will be summarized as mean ± (SD) or median (interquartile range) for continuous variables and group frequencies (%) for dichotomous or categorical variables.

As all patients are expected to achieve normothermia within the study period, the primary outcome of time to normothermia will be analyzed as a numeric outcome variable. Following validation of distributional assumptions the investigators will compare the time to normothermia between the two groups via t-test or Wilcoxon rank sum test as appropriate. It is expected that the patients will reach normothermia between 45 minutes and 6 hours after admission to the ICU.

By using a 2:1 matching ratio and a moderate level of variability (SD=1.3 hours) a study of 14 prospectively enrolled patients and 28 retrospectively matched patients would attain 82% power to detect a 1.25 hour difference between time to normothermia in the prospective group (active warming via traditional methods (ie forced air warming blankets) and Heated Humidified breathing circuits (HHBC) via ANAPOD Heated Humidification System® (ANAPOD), and the retrospective group (active warming via traditional methods (ie forced air warming blankets only) at alpha level 0.05.

Secondary numeric outcomes such as time to extubation, time to normal PH, and coagulopathy lab values will be analyzed by t-test or Wilcoxon rank sum test as appropriate. Differences in categorical outcomes between treatment groups will be analyzed via chi-square or fisher exact tests. As the patients will be matched on key confounders no further adjustment is expected to be necessary, so the moderate sample size should not limit the primary analysis. Potential subgroup analysis may be conducted in an exploratory analysis to determine if the treatment effect of ANAPOD warming is different by procedure type or patient/surgical characteristics.

Being tested
Heated Humidified Breathing Circuit and Forced Air Blanket
Keywords
Cardiopulmonary bypass, Afterdrop, Deep Hypothermic Circulatory Arrest, Heated Humidified Breathing Circuit
Medical subject headings
Hypothermia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Heated Humidified Breathing Circuit and Forced Air BlanketDevice

    Also called ANAPOD

    Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.

    Forced air warming blankets will be set at 42C for duration of rewarming.

Study groups in NCT03697122
Study groupRoleWhat they receive
HHBC and Forced Air WarmingExperimentalPatients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.
Receives: Device: Heated Humidified Breathing Circuit and Forced Air Blanket

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Normothermia

    Core temperature normothermia defined as >=36.5 C.

    Measured: up to 24 hours post admission to intensive care unit

Secondary outcomes (8)
  1. Time to Extubation

    Time from admission to time of extubation. Followup was truncated at 24 hours and if patient had not been extubated at that time they were assigned a value of 24 hours.

    Measured: up to 24 hours post admission to intensive care unit

  2. Coagulopathy as Measured by Need for Transfusion of Blood Product

    Assessed via number of transfusions of red blood cells, fresh frozen plasma, platelets, cryoprecipitate.

    Measured: 24 hours post admission to intensive care unit

  3. Metabolic Derangement as Measured by Time to Normal pH

    Assessed via blood gas analysis. Normal pH defined as 7.35-7.45.

    Measured: up to 24 hours post admission to intensive care unit

  4. Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of Prothrombin Time

    Laboratory assessment of Prothrombin Time with normal defined as 9.5-13.1 seconds.

    Measured: 24 hours post admission to intensive care unit

  5. Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of INR

    Laboratory assessment of international normalised ratio (INR) with normal defined as 0.9-1.1.

    Measured: 24 hours post admission to intensive care unit

  6. Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of Act Partial Thromboplastin Time

    Laboratory assessment of Act Partial Thromboplastin Time with normal defined as 26.8-37.1 seconds.

    Measured: 24 hours post admission to intensive care unit

  7. Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of Fibrinogen.

    Laboratory assessment of fibrinogen levels with normal defined as 213-435 mg/dL.

    Measured: 24 hours post admission to intensive care unit

  8. Number of Subjects With Abnormal Coagulopathy as Measured by Laboratory Assessment of Platelet Count

    Laboratory assessment of platelet count with normal defined as 150 - 450 x10ˆ9/L.

    Measured: 24 hours post admission to intensive care unit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Oct 2018
  2. Study start1 Apr 2019
  3. Primary completion15 Jun 2019
  4. Study completion15 Jun 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
The intervention group has only one arm. All patients will use active warming via traditional methods (ie forced air warming blankets) and Heated Humidified breathing circuits (HHBC) via ANAPOD Heated Humidification System® (ANAPOD). Those patients will be matched with a retrospective historical cohort of patients that received active warming via traditional methods only (forced air warming blankets).
Masking
None (open label)
Enrolment
14 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03697122
Sponsor's protocol ID
Pro00100711
Status last verified
Jul 2020
First submitted
27 Sep 2018
Last updated
15 Jul 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Heated Humidified Breathing Circuit and Forced Air Blanket in people with Hypothermia and Rewarming, run by Duke University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Jul 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Normothermia (time frame: up to 24 hours post admission to intensive care unit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in